| Literature DB >> 22019823 |
Carlo Patrono1, Felicita Andreotti, Harald Arnesen, Lina Badimon, Colin Baigent, Jean-Philippe Collet, Raffaele De Caterina, Dietrich Gulba, Kurt Huber, Steen Husted, Steen Dalby Kristensen, João Morais, Franz-Josef Neumann, Lars Hvilsted Rasmussen, Agneta Siegbahn, Philippe-Gabriel Steg, Robert F Storey, Frans Van de Werf, Freek Verheugt.
Abstract
The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22019823 DOI： 10.1093/eurheartj/ehr373
Source DB: PubMed Journal: Eur Heart J ISSN： 0195-668X Impact factor: 29.983